This segment focuses on the research and development of cell-based therapies for the treatment of diabetes. Pathfinder Cell Therapy is developing novel cell-derived therapies to address the underlying cell damage associated with diabetes. Research activities include identifying and isolating specific cell types, such as pancreatic cells, and developing methods for their delivery and integration into the body. The company utilizes advanced technologies in cell culture, tissue engineering, and regenerative medicine. The goal is to restore or improve pancreatic function in diabetic patients, leading to improved glucose control and reduced reliance on insulin. This segment aims to address the significant unmet medical need in diabetes treatment, offering a potential alternative to current therapies. The company's market positioning is as a pioneer in cell-based diabetes treatments, with potential for partnerships with pharmaceutical companies and research institutions. Regulatory and clinical aspects include preclinical studies, clinical trials, and seeking FDA approval for any developed therapies. The segment's future opportunities include expanding the application of cell-based therapies to other metabolic disorders and developing personalized treatment approaches.

This segment is dedicated to the development of cell-based therapies for renal diseases. Pathfinder Cell Therapy is actively researching and developing innovative cell-derived treatments to address the damage and dysfunction of kidney cells. The research and development activities involve identifying and isolating specific cell types, such as kidney cells, and developing methods for their delivery and integration into the body. The company utilizes advanced technologies in cell culture, tissue engineering, and regenerative medicine. The primary goal is to restore or improve kidney function in patients suffering from renal diseases, potentially reducing the need for dialysis or kidney transplants. This segment aims to address the significant unmet medical needs in renal disease treatment, offering a potential alternative to current therapies. The company's market positioning is as a pioneer in cell-based renal treatments, with potential for partnerships with pharmaceutical companies and research institutions. Regulatory and clinical aspects include preclinical studies, clinical trials, and seeking FDA approval for any developed therapies. The segment's future opportunities include expanding the application of cell-based therapies to other kidney-related disorders and developing personalized treatment approaches.

This segment focuses on the development of cell-based therapies for myocardial infarction (heart attack). Pathfinder Cell Therapy is researching and developing innovative cell-derived treatments to repair and regenerate damaged heart tissue. Research and development activities include identifying and isolating specific cell types, such as cardiac stem cells, and developing methods for their delivery and integration into the damaged heart. The company utilizes advanced technologies in cell culture, tissue engineering, and regenerative medicine. The primary goal is to restore heart function and improve patient outcomes after a myocardial infarction. This segment aims to address the significant unmet medical needs in cardiovascular disease treatment, offering a potential alternative to current therapies. The company's market positioning is as a pioneer in cell-based cardiac treatments, with potential for partnerships with pharmaceutical companies and research institutions. Regulatory and clinical aspects include preclinical studies, clinical trials, and seeking FDA approval for any developed therapies. The segment's future opportunities include expanding the application of cell-based therapies to other cardiovascular diseases and developing personalized treatment approaches.